These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10022219)

  • 1. Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma.
    Purohit A; Moreau L; Dietemann A; Seibert R; Pauli G; Wihlm JM; Quoix E
    Lung Cancer; 1998 Nov; 22(2):119-25. PubMed ID: 10022219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a.
    Soulié P; Ruffié P; Trandafir L; Monnet I; Tardivon A; Terrier P; Cvitkovic E; Le Chevalier T; Armand JP
    J Clin Oncol; 1996 Mar; 14(3):878-85. PubMed ID: 8622036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin, mitomycin, and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma.
    Metintas M; Ozdemir N; Uçgun I; Elbek O; Kolsuz M; Mutlu S; Metintas S
    Chest; 1999 Aug; 116(2):391-8. PubMed ID: 10453867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP).
    Parra HS; Tixi L; Latteri F; Bretti S; Alloisio M; Gravina A; Lionetto R; Bruzzi P; Dani C; Rosso R; Cosso M; Balzarini L; Santoro A; Ardizzoni A
    Cancer; 2001 Aug; 92(3):650-6. PubMed ID: 11505411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma.
    Trandafir L; Ruffié P; Borel C; Monnet I; Soulié P; Adams D; Cvitkovic E; Armand JP
    Eur J Cancer; 1997 Oct; 33(11):1900-2. PubMed ID: 9470855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
    Shin DM; Fossella FV; Umsawasdi T; Murphy WK; Chasen MH; Walsh G; Komaki R; McMurtrey MJ; Hong WK
    Cancer; 1995 Dec; 76(11):2230-6. PubMed ID: 8635025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma.
    Planting AS; van der Burg ME; Goey SH; Schellens JH; van den Bent MJ; de Boer-Dennert M; Stoter G; Verweij J
    Ann Oncol; 1995 Jul; 6(6):613-5. PubMed ID: 8573543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
    Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
    Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma.
    Ardizzoni A; Pennucci MC; Castagneto B; Mariani GL; Cinquegrana A; Magri D; Verna A; Salvati F; Rosso R
    Am J Clin Oncol; 1994 Feb; 17(1):80-2. PubMed ID: 8311014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
    Kasseyet S; Astoul P; Boutin C
    Cancer; 1999 Apr; 85(8):1740-9. PubMed ID: 10223568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma.
    Tsavaris N; Mylonakis N; Karvounis N; Bacoyiannis C; Briasoulis E; Skarlos D; Pavlidis N; Stamatelos G; Kosmidis P
    Lung Cancer; 1994 Sep; 11(3-4):299-303. PubMed ID: 7812707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma.
    O'Reilly EM; Ilson DH; Saltz LB; Heelan R; Martin L; Kelsen DP
    Cancer Invest; 1999; 17(3):195-200. PubMed ID: 10099658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I-II study of 5-fluorouracil, recombinant interferon alpha2a, and cisplatin in combination with external beam radiation therapy followed by surgery in patients with locally advanced carcinoma of the esophagus.
    Damle S; Beitler JJ; Haynes H; Camacho M; Wolf E; Wadler S
    Am J Clin Oncol; 1999 Aug; 22(4):391-5. PubMed ID: 10440197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of cisplatin and interferon-alpha 2a (Roferon-A) in patients with non-small cell lung cancer (NSCLC). An open phase II multicentre study.
    Kataja V; Yap A
    Eur J Cancer; 1995; 31A(1):35-40. PubMed ID: 7695976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
    Byrne MJ; Davidson JA; Musk AW; Dewar J; van Hazel G; Buck M; de Klerk NH; Robinson BW
    J Clin Oncol; 1999 Jan; 17(1):25-30. PubMed ID: 10458214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma.
    Kovac V; Zwitter M; Rajer M; Marin A; Debeljak A; Smrdel U; Vrankar M
    Anticancer Drugs; 2012 Feb; 23(2):230-8. PubMed ID: 22027538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
    Ilson DH; Sirott M; Saltz L; Heelan R; Huang Y; Keresztes R; Kelsen DP
    Cancer; 1995 May; 75(9):2197-202. PubMed ID: 7712428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study.
    Ardizzoni A; Rosso R; Salvati F; Fusco V; Cinquegrana A; De Palma M; Serrano J; Pennucci MC; Soresi E; Crippa M
    Cancer; 1991 Jun; 67(12):2984-7. PubMed ID: 2044044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force.
    Pennucci MC; Ardizzoni A; Pronzato P; Fioretti M; Lanfranco C; Verna A; Giorgi G; Vigani A; Frola C; Rosso R
    Cancer; 1997 May; 79(10):1897-902. PubMed ID: 9149015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.